Piezoelectric Ocular Fluid Delivery for Precise Preservative-Free Dosing

The patent employs a piezoelectric actuator that generates mechanical vibrations to eject medication from the reservoir through the aperture. This vibration-based ejection mechanism replaces gravity-dependent delivery, enabling precise control over medication volume and ejection timing while maintaining relatively simple device architecture. The piezoelectric material converts electrical signals into mechanical vibrations, providing controllable force for medication delivery.

The patent replaces traditional mechanical gravity-based delivery systems with a piezoelectric actuation system. The piezoelectric element converts electrical energy into mechanical vibrations, substituting the passive gravitational mechanism with an active, controllable electro-mechanical system that enables precise volume control and self-aligning delivery to the eye.

The patent utilizes periodic mechanical vibrations from the piezoelectric actuator to eject medication in controlled pulses rather than continuous flow. The periodic vibration pattern allows precise control over the timing and volume of each medication ejection, preventing overflow and accounting for the blinking reflex by delivering medication just before or during the blink cycle, thereby reducing medication loss.

The patent controls medication delivery by dynamically adjusting vibration parameters (frequency, amplitude, duration) of the piezoelectric actuator. By changing these parameters, the system can deliver precise volumes of medication that match the eye's capacity, preventing both insufficient delivery and overflow loss, while maintaining simple device architecture.

The patent extracts and eliminates the preservative component from the ophthalmic formulation while maintaining formulation stability through the sealed reservoir design and sterile barrier provided by the valve mechanism. This allows the delivery of preservative-free medication that reduces cytotoxic effects on the cornea and conjunctiva while preserving formulation integrity through physical containment rather than chemical preservation.

The patent introduces a sterile barrier valve mechanism as an intermediary between the formulation reservoir and the eye. This valve acts as a protective intermediary that prevents contamination of the preservative-free formulation while allowing controlled delivery of the medication to the eye, eliminating the need for cytotoxic preservatives while maintaining formulation reliability.

The patent implements a self-aligning delivery mechanism where the vibrating aperture automatically positions itself against the eye surface without requiring manual coordination. The mechanical vibration and aperture design enable the system to self-adjust and deliver medication directly to the cornea, eliminating the need for user coordination while preventing contamination by avoiding tip contact with the eye.

The patent replaces the manual mechanical dropper system with a piezoelectrically-driven vibration system. This substitution eliminates the need for manual coordination and control, as the electronic actuator provides precise, automated delivery. The system replaces manual tip positioning with automated vibration-based ejection, reducing both operational difficulty and contamination risk.